Expression of cannabinoid receptors CB1 and CB2 in canine cutaneous mast cell tumours.
Cannabinoid
Dog
Histopathology
Immunohistochemistry
Mast cell tumor
Journal
Research in veterinary science
ISSN: 1532-2661
Titre abrégé: Res Vet Sci
Pays: England
ID NLM: 0401300
Informations de publication
Date de publication:
20 Dec 2022
20 Dec 2022
Historique:
received:
17
04
2022
revised:
27
08
2022
accepted:
13
09
2022
pubmed:
1
10
2022
medline:
2
11
2022
entrez:
30
9
2022
Statut:
ppublish
Résumé
Cannabinoid receptors (CB1 and CB2) belong to endocannabinoid system (ECS), which is also composed from endocannabinoids and the enzymatic systems involved in their biosynthesis and degradation. The expression of CB1 and CB2 have been previously identified in normal canine mast cell and in atopic dermatitis. Canine cutaneous mast cell tumours (cMCTs) are among the most common cutaneous neoplasms in dogs and have a highly variable clinical behaviour. Expression of CB1-CB2 was assessed by means of immunohistochemistry in thirty-seven dogs (from 2019 to 2021) with proven histological diagnosis of cMCT. Dogs were divided in two groups according to the Kiupel's grading system: high-grade (HG) cMCT and low-grade (LG) cMCT. A semiquantitative (score 0-3) and quantitative assessment of immunoreactivity (IR) was performed for each case. Our results show that there CB1 and CB2 are highly expressed in LG- cMCT, in contrast to HG- cMCT.
Identifiants
pubmed: 36179546
pii: S0034-5288(22)00294-6
doi: 10.1016/j.rvsc.2022.09.013
pii:
doi:
Substances chimiques
Receptor, Cannabinoid, CB1
0
1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide
15580-20-8
CME-Carbodiimide
2491-17-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
530-536Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflicts of interest.